Repligen
| Company type | Public |
|---|---|
| Nasdaq: RGEN S&P 400 Component | |
| Industry | Biotechnology Laboratory equipment |
| Founded | 1981 |
| Founders | Alexander Rich Paul Schimmel |
| Headquarters | Waltham, Massachusetts , United States |
Key people | Olivier Loeillot (president and CEO [as of 2024]) |
| Products | Materials used in the manufacture of biological drugs |
| Revenue | US$634 million (2024) |
Number of employees | Over 1,900 globally |
| Website | repligen |
Repligen Corporation is a global life sciences company devoted to the development and commercialization of innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs.2025 The company is based in Waltham, Massachusetts,2014 and was incorporated in Delaware in 1981. A public company, Repligen is listed on the NASDAQ exchange under the symbol RGEN. As of 2025, Repligen employs over 1,900 employees globally and serves primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide.